Recent Articles

November 25, 2014 10:53 am
Mwai Ngibuini, ambr250 Product Manager, Sartorius Stedim Biotech | TAP Biosystems
With new mAb drugs such as Kadcyla costing over 100,000 Euros per year, the price per patient for these therapies is considerably more than small molecule drug treatments. One reason for this is that these therapies cost more to manufacture than small molecules. By using mini scale bioreactor models to determine optimum scale-up bioprocess parameters in fed-batch culture could speed up process development and reduce manufacturing costs.
November 20, 2014 10:08 am
Nathan Furr and Jeff Dyer
The average cost of developing an approved therapy is around $4.3 billion dollars for companies with three or more approved therapies, according to an analysis completed by Forbes. Imagine, then, our surprise when we discovered a biotechnology company outside of New York City that had developed three approved therapies for an average cost of $0.7 billion dollars – less than 20 percent of the industry average.
November 13, 2014 2:39 pm
Deepak Mistry and Steven Lynum, Panasonic Healthcare Corporation of North America
Clean rooms are the standard for cGMP-compliant manufacturing, but the significant time and high costs of manufacturing and maintenance, as well as the lack of mobility, makes them difficult to justify.        
November 13, 2014 11:37 am
Mark Florez, Product Manager, Clariant Healthcare Packaging; Randy Caspersen, Vice President, Sales and Marketing, Omega Design Incorporated
As global demand for bottle-packaged pharmaceuticals grows, incremental upgrades in desiccant canister design yield substantial performance improvements.                 
November 6, 2014 2:37 pm
Al Fosco, Frigel North America
Like so many industries, pharmaceutical processing is increasingly focused on improving the operational energy efficiency. One challenge that often stands in the way: cleanrooms. In these facilities, energy efficiency understandably takes a back seat to the mission of clean production. As a result, due to FDA-required filtration, high-performance processing machines and other factors, cleanrooms are energy intensive.
October 31, 2014 10:43 am
Nikita Ernst, Associate Editor
SAFC, a global supplier of a a wide range of services to the biopharm and pharmaceutical industry, has recently expanded their Madison, Wisconsin facilities to neighboring Verona to rev up their high-potency API manufacturing capabilities.
October 31, 2014 11:19 am
Sarfaraz K. Niazi, Ph.D., Founding Chairman and CEO, Therapeutic Proteins International
Biosimilars have increasingly become an important and somewhat controversial topic in the healthcare space. Depending on who one speaks to, the opinion on biosimilars changes. However, there are certain truths that all stakeholders should keep in mind.
October 31, 2014 3:03 pm
Nic Michel, General Manager, North America, Pharma Technology Inc.
Dust has always been an unwanted byproduct of tablet manufacturing. In a perfect world, all powder would flawlessly flow into the hopper, and 100% of the product would emerge as finished tablets. In practice, though, most tablet presses are so inundated with dust after an eight-hour run that they form miniature snow piles on both sides of the feeder, and build-ups of material occur around the takeoff bar and recirculation channel.
Subscribe to Pharmaceutical Processing